Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Laura L. Fernandes"'
Autor:
Helmneh M. Sineshaw, Christina M. Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M. Sarpong, Claire Bai, Andrew J. Belli, Laura L. Fernandes, Ching‐Kun Wang
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Background Although initial treatment of diffuse large B‐cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) can be effective, up to 50% of patients will develop refractory or relapse
Externí odkaz:
https://doaj.org/article/b73929874bc649e599060c515c402585
Autor:
Kathleen Maignan, Lola A. Fashoyin-Aje, Aracelis Z. Torres, Laura L. Fernandes, Thomas Gwise, Shrujal B. Baxi, James P. Roose, Donna R. Rivera, Yuan Li Shen, Paul G. Kluetz, Nicole J. Gormley
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-6 (2022)
Abstract This retrospective observational study evaluated racial disparities among Black and White patients with multiple myeloma (MM). We included patients from a longitudinal de-identified EHR-derived database who had ≥2 visits recorded on or aft
Externí odkaz:
https://doaj.org/article/4676e1178d1f40689b1186a68dd087aa
Autor:
Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, Christina M. Zettler, Ching-Kun Wang
Publikováno v:
Cancer Treatment and Research Communications, Vol 36, Iss , Pp 100742- (2023)
Introduction/ Background: Surgical resection remains standard of care for patients with early-stage non-small cell lung cancer (NSCLC), but research shows that adjuvant therapy can reduce the risk of disease recurrence. Our objective was to character
Externí odkaz:
https://doaj.org/article/933944f54c9040df8d044d4ec368b8f6
Autor:
Laura L. Fernandes, Jiaxi Zhou, Bindu Kanapuru, Erica Horodniceanu, Thomas Gwise, Paul G. Kluetz, Vishal Bhatnagar
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 8, Pp 1-6 (2021)
Abstract Over the past 13 years, there have been advances in characterizing the patient experience in oncology trials, primarily using patient-reported outcomes (PROs). This review aims to provide details on the PRO measures and analyses used in mult
Externí odkaz:
https://doaj.org/article/79a8fb887fae4215a318dfe915d3e787
Autor:
Anne Shah, Jon Apple, Andrew J. Belli, Anna Barcellos, Eric Hansen, Laura L. Fernandes, Ching-Kun Wang
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::599a55f25edd1e7cc69bde1bb31d62c1
https://doi.org/10.6004/jnccn.2022.7184
https://doi.org/10.6004/jnccn.2022.7184
Autor:
Bindu Kanapuru, Laura L. Fernandes, Lola A. Fashoyin-Aje, Andrea C. Baines, Vishal Bhatnagar, Rachel Ershler, Thomas Gwise, Paul Kluetz, Richard Pazdur, Elizabeth Pulte, Yuan-Li Shen, Nicole Gormley
Publikováno v:
Blood Advances. 6:1684-1691
African Americans (AAs) have a higher incidence of multiple myeloma (MM) than White patients. Mortality is also higher in AAs compared with White patients. AAs more commonly have immunoglobulin H translocations t(11;14) and t(14;16) compared with Whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::910e6bc6841ce62d9e83467c0958c87b
https://doi.org/10.1182/bloodadvances.2021005482
https://doi.org/10.1182/bloodadvances.2021005482
Autor:
Vishal Bhatnagar, Laura L. Fernandes, Paul G. Kluetz, Jiaxi Zhou, Thomas Gwise, Erica G. Horodniceanu, Bindu Kanapuru
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 8, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Over the past 13 years, there have been advances in characterizing the patient experience in oncology trials, primarily using patient-reported outcomes (PROs). This review aims to provide details on the PRO measures and analyses used in multiple myel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f96e1e2117f4a9b8bd902467f90f4811
https://doaj.org/article/79a8fb887fae4215a318dfe915d3e787
https://doaj.org/article/79a8fb887fae4215a318dfe915d3e787
Autor:
Amna Ibrahim, Chana Weinstock, Sundeep Agrawal, Kirsten B. Goldberg, Julia A. Beaver, Shenghui Tang, Elaine Chang, Daniel L. Suzman, Jamie Renee Brewer, Richard Pazdur, Rajeshwari Sridhara, Harpreet Singh, Laura L. Fernandes, James Xu, Lijun Zhang, Joyce Cheng, Erik Bloomquist, Marc R. Theoret, Diqiong (Joan) Xie
Publikováno v:
Clinical Cancer Research. 26:6406-6411
The development and review of combination drug regimens in oncology may present unique challenges to investigators and regulators. For regulatory approval of combination regimens, it is necessary to demonstrate the contribution of effect of each mono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54c8193b4f314849342452c5acd99f5
https://doi.org/10.1158/1078-0432.ccr-19-4229
https://doi.org/10.1158/1078-0432.ccr-19-4229
Autor:
Paul G. Kluetz, Pengfei Song, Preeti Narayan, Jianghong Fan, Emily Li, Yutao Gong, Xiao Hong Chen, Kirsten B. Goldberg, Laleh Amiri-Kordestani, Anand Pathak, Tatiana M. Prowell, Jeffrey D. Seidman, Julia A. Beaver, Laura L. Fernandes, Xing Wang, Bellinda L. King-Kallimanis, Shenghui Tang, Xinyuan Zhang, Francisca Reyes Turcu, Anamitro Banerjee, Katherine Windsor, Soma Ghosh, Steve Y. Rhieu, Jingyu Yu, Deb K. Chatterjee, Gerlie Geiser, Reena Philip, Marc R. Theoret, Jennifer J Gao, Tiffany K. Ricks, Wei Chen, Richard Pazdur, Xiling Jiang, Junshan Qiu
Publikováno v:
Clin Cancer Res
On May 24, 2019, the FDA granted regular approval to alpelisib in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, HER2-negative, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e529581922a1e254adc0623b5fd78f
https://pubmed.ncbi.nlm.nih.gov/33168657
https://pubmed.ncbi.nlm.nih.gov/33168657
Autor:
Sanjeeve Balasubramaniam, Rosane Charlab, Sara Horton, Chao Liu, Hisani N. Horne, Robert N. Schuck, Kim J. Robertson, Laura L. Fernandes, Julia A. Beaver, William F. Pierce, Anamitro Banerjee, Todd R. Palmby, Xiao Hong Chen, Geoffrey Kim, Jingyu Yu, Pengfei Song, Kirsten B. Goldberg, Eunice Y. Lee, Richard Pazdur, Jinzhong Liu, Rajeshwari Sridhara, Haw Jyh Chiu, Reena Philip, Shenghui Tang, Xing Wang, Sarah J. Schrieber
Publikováno v:
Clinical Cancer Research. 23:7165-7170
On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)–associated advanced ovarian cancer who have been treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abffb888681f499bd863b494c2fe3e6f
https://doi.org/10.1158/1078-0432.ccr-17-1337
https://doi.org/10.1158/1078-0432.ccr-17-1337